PRESS-RELEASE ·Filed Apr 8, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should monitor the May 7 earnings call for actual financial performance and potential guidance updates; this release only sets expectations for disclosure timing.
Final — all horizons settled through T+60d
CRNX ▲ +6.06% at T+60d
NEUTRAL call ✓ call won +6.06% · α vs SPY -4.73% · entry $39.63 → $42.03
T+1d
-0.48%
call -0.48% · α -0.42%
$39.44
settled 6mo ago
T+5d
-1.54%
call -1.54% · α -4.73%
$39.02
settled 6mo ago
T+20d
+5.25%
call +5.25% · α -2.32%
$41.71
settled 5mo ago
T+60d
+6.06%
call +6.06% · α -4.73%
$42.03
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Crinetics Pharmaceuticals announced a future earnings date for Q1 2026 but did not release actual financial results in this press release. The company reiterated its business update and pipeline progress without providing any new financial data for the reported period.
Key Facts
- Crinetics will report Q1 2026 financial results on May 7, 2026, after market close.
- No financial results were released in this announcement — only a schedule for future reporting.
- Management will host a conference call to discuss results and provide a business update.
- The press release emphasizes pipeline progress, including PALSONIFY™ and late-stage candidate atumelnant.
- No financial metrics (revenue, EPS, guidance) were disclosed for Q1 2026 or any prior period in this filing.
Financial Impact
No financial impact from this filing — no results released.
Risk Factors
- Lack of financial disclosure limits near-term trading catalysts.
- Recent insider selling ($651K over 30 days) may signal caution ahead of earnings.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270499 |
15 reports for CRNX
78% Hit rate best @ T+20▲ +138.24%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (38h 31m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access